NCT04343885View on ClinicalTrials.gov

In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

April 21, 2020

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Metastatic Hormone Naive Prostate Cancer
Interventions
DRUG

177Lu-PSMA-617

Patients will be given 7.5GBq of 177Lu-PSMA every 6 weeks for 2 cycles.

DRUG

Docetaxel

Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles

Trial Locations (12)

2010

St Vincent's Hospital Sydney, Sydney

2050

Chris O'Brien Lifehouse, Sydney

2065

Royal North Shore, St Leonards

2170

Liverpool Hospital, Liverpool

3000

Peter MacCallum Cancer Centre, Melbourne

Alfred Hospital, Prahran

3084

Austin Health, Melbourne

3144

Cabrini Hospital, Malvern

4029

Royal Brisbane and Women's Hospital, Brisbane

5000

Royal Adelaide Hospital, Adelaide

6009

Sir Charles Gairdner Hospital, Nedlands

6150

Fiona Stanley Hospital, Murdoch

Sponsors
All Listed Sponsors
collaborator

Movember Foundation

OTHER

collaborator

Prostate Cancer Research Alliance

UNKNOWN

collaborator

United States Department of Defense

FED

collaborator

Advanced Accelerator Applications

INDUSTRY

collaborator

Australia's Nuclear Science and Technology Organisation (ANSTO)

UNKNOWN

collaborator

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

OTHER

collaborator

Australasian Radiopharmaceutical Trials network (ARTnet)

UNKNOWN

collaborator

Centre for Biostatistics and Clinical Trials (BaCT)

UNKNOWN

lead

Peter MacCallum Cancer Centre, Australia

OTHER